Logo image of MREO

MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Fundamental Analysis

NASDAQ:MREO - Nasdaq - US5894921072 - ADR - Currency: USD

2.85  -0.02 (-0.7%)

After market: 2.85 0 (0%)

Fundamental Rating

3

MREO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. MREO has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MREO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year MREO has reported negative net income.
In the past 5 years MREO reported 4 times negative net income.
MREO had a negative operating cash flow in each of the past 5 years.
MREO Yearly Net Income VS EBIT VS OCF VS FCFMREO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

MREO has a Return On Assets of -74.00%. This is in the lower half of the industry: MREO underperforms 67.20% of its industry peers.
MREO has a Return On Equity of -90.54%. This is comparable to the rest of the industry: MREO outperforms 48.13% of its industry peers.
Industry RankSector Rank
ROA -74%
ROE -90.54%
ROIC N/A
ROA(3y)-25.3%
ROA(5y)-75.27%
ROE(3y)-33.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MREO Yearly ROA, ROE, ROICMREO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800 1K

1.3 Margins

MREO has a better Gross Margin (74.26%) than 85.03% of its industry peers.
MREO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MREO Yearly Profit, Operating, Gross MarginsMREO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

8

2. Health

2.1 Basic Checks

MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MREO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MREO has been increased compared to 5 years ago.
Compared to 1 year ago, MREO has an improved debt to assets ratio.
MREO Yearly Shares OutstandingMREO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
MREO Yearly Total Debt VS Total AssetsMREO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 8.02 indicates that MREO is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.02, MREO belongs to the best of the industry, outperforming 85.03% of the companies in the same industry.
MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.02
ROIC/WACCN/A
WACC9.26%
MREO Yearly LT Debt VS Equity VS FCFMREO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 6.10 indicates that MREO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.10, MREO is in the better half of the industry, outperforming 61.68% of the companies in the same industry.
MREO has a Quick Ratio of 6.10. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
MREO's Quick ratio of 6.10 is fine compared to the rest of the industry. MREO outperforms 62.03% of its industry peers.
Industry RankSector Rank
Current Ratio 6.1
Quick Ratio 6.1
MREO Yearly Current Assets VS Current LiabilitesMREO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

4

3. Growth

3.1 Past

MREO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.53%, which is quite impressive.
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MREO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.02% yearly.
MREO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 93.89% yearly.
EPS Next Y-11.87%
EPS Next 2Y-97.44%
EPS Next 3Y11.54%
EPS Next 5Y35.02%
Revenue Next Year-100%
Revenue Next 2Y63.98%
Revenue Next 3Y65.67%
Revenue Next 5Y93.89%

3.3 Evolution

MREO Yearly Revenue VS EstimatesMREO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MREO Yearly EPS VS EstimatesMREO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MREO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MREO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MREO Price Earnings VS Forward Price EarningsMREO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MREO Per share dataMREO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-97.44%
EPS Next 3Y11.54%

0

5. Dividend

5.1 Amount

No dividends for MREO!.
Industry RankSector Rank
Dividend Yield N/A

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (2/21/2025, 8:00:01 PM)

After market: 2.85 0 (0%)

2.85

-0.02 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners70.36%
Inst Owner Change-99.58%
Ins Owners0.87%
Ins Owner Change20.12%
Market Cap442.16M
Analysts88.57
Price Target7.53 (164.21%)
Short Float %23.06%
Short Ratio6.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-668.13%
Min EPS beat(2)-886.64%
Max EPS beat(2)-449.62%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.16%
PT rev (3m)2.58%
EPS NQ rev (1m)-185.84%
EPS NQ rev (3m)-132.2%
EPS NY rev (1m)-87.94%
EPS NY rev (3m)-121.21%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.22
P/FCF N/A
P/OCF N/A
P/B 6.1
P/tB 6.16
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.06
BVpS0.47
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74%
ROE -90.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.26%
FCFM N/A
ROA(3y)-25.3%
ROA(5y)-75.27%
ROE(3y)-33.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.1
Quick Ratio 6.1
Altman-Z 8.02
F-ScoreN/A
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)28.58%
Cap/Depr(5y)17.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-11.87%
EPS Next 2Y-97.44%
EPS Next 3Y11.54%
EPS Next 5Y35.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y63.98%
Revenue Next 3Y65.67%
Revenue Next 5Y93.89%
EBIT growth 1Y34.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.62%
EBIT Next 3Y10.49%
EBIT Next 5YN/A
FCF growth 1Y54.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.59%
OCF growth 3YN/A
OCF growth 5YN/A